Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 8;13(1):42.
doi: 10.3390/toxins13010042.

Botulinum Toxin in Movement Disorders: An Update

Charenya Anandan  1 , Joseph Jankovic  1
Affiliations
Review

Botulinum Toxin in Movement Disorders: An Update

Charenya Anandan et al. Toxins (Basel). .

Abstract

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson's disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

Keywords: Parkinson’s disease; botulinum toxin; bruxism; dyskinesia; dystonia; movement disorders; myoclonus; restless legs syndrome; tics; tremors.

PubMed Disclaimer

Conflict of interest statement

Jankovic has received research or training grants from AbbVie Inc.; Allergan, Inc.; Dystonia Coalition; Merz Pharmaceuticals; and Revance Therapeutics, Inc. Jankovic has served as a consultant for Aeon Biopharma, and Revance Therapeutics. Jankovic is a member of the editorial board of The Botulinum Journal and Toxins.

Figures

Figure 1
Figure 1
BoNT in Movement disorders.
See this image and copyright information in PMC

References

    1. Padda I.S., Tadi P. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2020. Botulinum Toxin. - PubMed
    1. Pirazzini M., Rossetto O., Eleopra R., Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol. Rev. 2017;69:200–235. doi: 10.1124/pr.116.012658. - DOI - PMC - PubMed
    1. Rossetto O., Pirazzini M., Fabris F., Montecucco C. Handbook of Experimental Pharmacology. Springer; Berlin/Heidelberg, Germany: 2020. Botulinum Neurotoxins: Mechanism of Action. - DOI - PubMed
    1. Lonati D., Schicchi A., Crevani M., Buscaglia E., Scaravaggi G., Maida F., Cirronis M., Petrolini V.M., Locatelli C.A. Foodborne botulism: Clinical diagnosis and medical treatment. Toxins. 2020;12:509. doi: 10.3390/toxins12080509. - DOI - PMC - PubMed
    1. Wang Y., Fry H.C., Skinner G.E., Schill K.M., Duncan T.V. Detection and Quantification of Biologically Active Botulinum Neurotoxin Serotypes A and B Using a Förster Resonance Energy Transfer-Based Quantum Dot Nanobiosensor. ACS Appl. Mater. Interfaces. 2017;9:18. doi: 10.1021/acsami.7b08736. - DOI - PubMed

MeSH terms

LinkOut - more resources